Insulin regulates development, metabolism, and lifespan via a conserved PI3K/Akt pathway that promotes cytoplasmic sequestration of FoxO transcription factors. The regulation of nuclear FoxO is poorly understood. In the nematode Caenorhabditis elegans, insulin-like signaling functions in larvae to inhibit dauer arrest and acts during adulthood to regulate lifespan. In a screen for genes that modulate C. elegans insulin-like signaling, we identified eak-3, which encodes a novel protein that is specifically expressed in the two endocrine XXX cells. The dauer arrest phenotype of eak-3 mutants is fully suppressed by mutations in daf-16/FoxO, which encodes the major target of C. elegans insulin-like signaling, and daf-12, which encodes a nuclear receptor regulated by steroid hormones known as dafachronic acids. eak-3 mutation does not affect DAF-16/ FoxO subcellular localization but enhances expression of the direct DAF-16/FoxO target sod-3 in a daf-16/FoxO-and daf-12-dependent manner. eak-3 mutants have normal lifespans, suggesting that EAK-3 decouples insulin-like regulation of development and longevity. We propose that EAK-3 activity in the XXX cells promotes the synthesis and/or secretion of a hormone that acts in parallel to AKT-1 to inhibit the expression of DAF-16/FoxO target genes. Similar hormonal pathways may regulate FoxO target gene expression in mammals.
Introduction
During early postembryonic development of the nematode Caenorhabditis elegans, animals respond to unfavorable conditions by arresting in an alternative larval stage called dauer. Dauers are long-lived and equipped to withstand suboptimal environments. Upon improvement of ambient conditions, dauers resume larval development and progress to adulthood. The major influence on dauer arrest is a constitutively synthesized pheromone that induces dauer arrest and serves as an indicator of population density. Pheromone responses are modulated by temperature and food availability (Riddle, 1988) .
Dauer arrest is regulated by a complex signal transduction network. In the amphid neurons, which are in direct contact with the external environment, the DAF-11 transmembrane guanylyl cyclase (GC) prevents dauer arrest (Birnby et al., 2000) . In a subset of these sensory neurons, DAF-11/GC promotes the synthesis of DAF-7, a transforming growth factor-β (TGFβ) homolog, and DAF-28, an insulin-like molecule (Li et al., 2003; Murakami et al., 2001; Ren et al., 1996; Schackwitz et al., 1996) . DAF-7/TGFβ and DAF-28/insulin are likely secreted and activate TGFβ receptor-like (DAF-1/TGFβRI and DAF-4/TGFβRII) (Estevez et al., 1993; Georgi et al., 1990 ) and insulin receptor-like (DAF-2/InsR) (Kimura et al., 1997) molecules that are expressed throughout the animal. Each of these receptors activates an evolutionarily conserved signaling cascade that functions in most if not all tissues in the animal. A hormonal pathway also regulates dauer arrest and is defined by the cytochrome P450 homolog DAF-9/CYP27A1 (Gerisch et al., 2001; Jia et al., 2002) , the nuclear receptor DAF-12 (Antebi et al., 2000) , the Rieske oxygenase homolog DAF-36 (Rottiers et al., 2006) , and the Niemann-Pick C disease gene homologs NCR-1 and NCR-2 (Sym et al., 2000) .
DAF-2/InsR regulates development, metabolism, and longevity through a conserved PI3K/Akt/FoxO signaling pathway (Finch and Ruvkun, 2001; Kenyon, 2005; Taniguchi et al., 2006) . Two Akt/PKB homologs, AKT-1 and AKT-2, have distinct and overlapping functions in this pathway (Hertweck et al., 2004; Paradis and Ruvkun, 1998) . Reduction of DAF-2/ InsR signaling results in dauer arrest in replete environments (Riddle, 1988) . DAF-2/InsR pathway mutants also exhibit increased fat storage (Ashrafi et al., 2003; Kimura et al., 1997) and extended lifespan (Kenyon et al., 1993; Morris et al., 1996; Paradis et al., 1999; Wolkow et al., 2002) . All DAF-2/InsR pathway mutant phenotypes require the FoxO transcription factor DAF-16 (Ashrafi et al., 2003; Dorman et al., 1995; Gottlieb and Ruvkun, 1994) , indicating that the major target of DAF-2/InsR signaling is DAF-16/FoxO. FoxO transcription factors are regulated by a number of posttranslational modifications, including phosphorylation, ubiquitination, and acetylation (Barthel et al., 2005; Vogt et al., 2005) . However, the biological relevance of many of these modifications remains to be demonstrated in intact organisms, and the physiological inputs that regulate many of these events have not been identified.
Several lines of evidence suggest that in C. elegans, DAF-16/FoxO regulatory inputs distinct from PI3K/Akt exist. For example, activating mutations in pdk-1 (Paradis et al., 1999) and akt-1 (Paradis and Ruvkun, 1998) suppress dauer arrest in age-1/PI3K mutant backgrounds more strongly than they do in daf-2/InsR mutant backgrounds. Likewise, a weak daf-18/PTEN loss-of-function allele suppresses dauer arrest in age-1/PI3K mutants but not in daf-2/InsR mutants (Gil et al., 1999; Gottlieb and Ruvkun, 1994; Inoue and Thomas, 2000; Ogg and Ruvkun, 1998; Vowels and Thomas, 1992) . Furthermore, DAF-16/FoxO that localizes to the nucleus as a consequence of either loss-of-function of the 14-3-3 protein FTT-2 (Berdichevsky et al., 2006) or mutation of the consensus AKT phosphorylation sites (Lin et al., 2001 ) is not fully active, suggesting the existence of an AKT-independent mechanism of inhibition of nuclear DAF-16/FoxO activity. Multiple genetic screens have failed to reveal the identity of the molecules that comprise this parallel pathway.
We now report the cloning and characterization of eak-3, a gene encoding a novel plasma membrane-associated protein that functions in the endocrine XXX cells. Our results define a role for EAK-3 in the nonautonomous regulation of nuclear DAF-16/FoxO activity.
Materials and methods

Strains
The following strains were used: N2 Bristol (wild-type), daf-2(e1370), akt-1(mg306), eak-3(mg344), eak-4(mg348), sdf-9(ut187), eak-6(mg329), daf-16(mgDf47), daf-3(mgDf90), osm-5(p813), sqt-1(sc13) age-1(hx546), daf-18(e1375), akt-1(mg144), daf-9(k182), daf-12(rh61rh411), daf-36(k114), akt-2(ok393), pdk-1(sa709), ncr-1(nr2022), and ncr-2(nr2023). akt-1(mg306) is a molecular null allele (Hu et al., 2006) , and akt-1(mg144) is a gain-offunction allele that was isolated as a suppressor of the dauer arrest phenotype of an age-1 null allele (Paradis and Ruvkun, 1998) . ncr-1(nr2022) and ncr-2 (nr2023) were provided by Dr. Weiqing Li (University of Washington, Seattle, WA, USA), and daf-9(k182) and daf-36(k114) were provided by Dr. Adam Antebi (Baylor College of Medicine, Houston, TX, USA). Double and triple mutant strains were constructed using standard genetic techniques, and genotypes were confirmed using either restriction fragment length polymorphisms or PCR polymorphisms, with the following exceptions. The presence of the age-1(hx546) allele was inferred based on linkage to sqt-1(sc13), and the presence of pdk-1(sa709) in the eak-3;pdk-1 double mutant was inferred from the strong 25°C dauer arrest phenotype.
DAF-16∷GFP localization was assayed using strain TJ356 (zIs356) IV, which contains a translational fusion of the DAF-16A isoform in-frame to GFP (Henderson and Johnson, 2001 ). sod-3p∷GFP activity was assayed using strain CF1553 (muIs84), which contains a transgene consisting of the sod-3 promoter fused to a nuclear-localized GFP reporter (Libina et al., 2003) .
eak-3 mutant isolation, SNP mapping, sequencing of mutant alleles, and cDNA isolation Isolation, mapping, and sequencing of eak-3 alleles and isolation of an eak-3 cDNA was performed as described for eak-4, sdf-9, and eak-6 (Hu et al., 2006) , except that the 5′/3′ RACE kit was purchased from Invitrogen (Carlsbad, CA, USA). The 5′ and 3′ ends of the longest eak-3 cDNAs identified correspond to nucleotides 19625 and 18124, respectively, of YAC Y92C3A. We did not identify any spliced leader sequences at the 5′ ends.
Dauer and lifespan assays
Dauer and lifespan assays were performed as previously described (Hu et al., 2006) . All dauer assays at 27°C were performed in blinded fashion. P-values for differences in mean lifespans were calculated using the two-sided heteroscedastic Student's T-test (Microsoft Excel X).
RNAi
Feeding RNAi was performed as described (Hu et al., 2006) .
GFP and RFP reporter constructs
The eak-3p∷GFP promoter fusion was generated as follows: a 1203-bp genomic DNA fragment corresponding to nucleotides 19605-20807 of YAC Y92C3A (annotated at the National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/) was PCR-amplified using primers tailed with BglII linkers. The BglII-digested PCR product was subcloned into BamHIdigested pPD95.67 (a gift from Dr. Andrew Fire, Stanford University, Palo Alto, CA, USA) to generate eak-3p∷GFP. Fragment orientation was confirmed by restriction digestion. Plasmids were purified using columns from Qiagen (Venlo, The Netherlands). The sdf-9p∷RFP construct marking the cytoplasm of the XXX cells has been described (Hu et al., 2006) . The EAK-3∷GFP translational fusion was generated using overlap extension PCR (Hobert, 2002) . A genomic DNA fragment corresponding to nucleotides 18161-20807 of YAC Y92C3A (encompassing the eak-3 promoter and open reading frame up to but not including the translation termination codon) was PCR-amplified and fused to a PCR product containing GFP and the unc-54 3′ UTR that was amplified from pPD95.75 (also a gift from Dr. Andrew Fire). The EAK-3∷GFP G2A Nmyristoylation mutant was constructed using overlap extension PCR by incorporating nucleotide changes resulting in mutation of glycine at residue 2 of EAK-3 to alanine. The final fusion PCR product was sequenced to confirm the presence of the G2A mutation. Fusion PCR products were purified using the Qiaquick PCR purification kit (Qiagen, Venlo, The Netherlands).
Transgenic animals were generated and colocalization studies performed as described previously (Hu et al., 2006) . In colocalization experiments (Figs. 4A and B), animals were visualized using a Zeiss Axioplan 2 upright microscope and analyzed using OpenLab imaging software (Improvision, Inc., Lexington, MA, USA). Animals harboring wild-type and G2A mutant EAK-3∷GFP (Fig.  4C) , and animals harboring DAF-16∷GFP and sod-3p∷GFP reporter constructs (Figs. 5 and S3) were visualized using an Olympus BX61 upright microscope and analyzed using SlideBook 4.1 digital microscopy software (Intelligent Imaging Innovations, Inc., Denver, CO, USA). Animals were mounted on 2% agarose pads in the presence of PBS with 10 mM sodium azide, visualized, and photographed immediately after mounting.
Real-time PCR
Synchronized wild-type and mutant animals grown at 25°C were harvested 26 h after egg prep, and total RNA was prepared from ∼ 300 to 400 animals per strain using TRI reagent (Molecular Research Center, Inc., Cincinnati, OH, USA) according to the manufacturer's instructions. First-strand cDNA was synthesized using SuperScript™ III (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. sod-3 mRNA was quantified with SYBR® Green-based detection using an Eppendorf realplex 2 Mastercycler (Eppendorf North America, Westbury, NY, USA) according to the manufacturer's protocol. Forty cycles of PCR (95°C for 15 s followed by 60°C for one min) were performed on cDNA template. Each sample was assayed in duplicate. sod-3 mRNA levels were normalized to act-1 mRNA levels. sod-3 primers used were 5′ TATTAAGCGCGACTTCGGTTCCCT 3′ and 5′ CGTGCTCCCAAACGT-CAATTCCAA 3′. act-1 primers have been described .
Results
eak-3 mutants exhibit enhanced dauer arrest
In C. elegans, DAF-2/InsR signaling prevents dauer arrest, and the degree of reduction in DAF-2/InsR signaling in any given pathway mutant is proportional to the strength of the dauer arrest phenotype; i.e., animals with greater reductions in DAF-2/InsR signaling are more likely to arrest as dauers. AKT-1 functions downstream of DAF-2/InsR and AGE-1/PI3K (Paradis and Ruvkun, 1998) and promotes development to adulthood by phosphorylating DAF-16/FoxO and promoting its cytoplasmic sequestration (Hertweck et al., 2004; Lee et al., 2001; Lin et al., 2001) . akt-1(mg306) is a molecular null allele that has a weak dauer arrest phenotype (Hu et al., 2006) , indicating that akt-1 mutation reduces but does not fully abolish DAF-2/InsR signaling.
To identify novel genes that function in parallel to AKT-1 to regulate dauer arrest, we performed a genetic screen for mutants that enhance the akt-1(mg306) dauer arrest phenotype (eak mutants). This screen, as well as three genes identified in this screen, eak-4, sdf-9, and eak-6, has been described elsewhere (Hu et al., 2006) . The eak-3 gene is defined by three alleles, mg331, mg335, and mg344, that complement eak-4, sdf-9, and eak-6 mutants but do not complement each other.
eak-3 mutants have a very weak dauer arrest phenotype at 25°C but strongly enhance the dauer arrest phenotype of akt-1(mg306) (Fig. 1A ). eak-3;akt-1 double mutants arrest as dauers at 25°C to the same extent as daf-2(e1370) mutants. The eak-3 mutant phenotype is comparable to that of eak-4, sdf-9, and eak-6 mutants that emerged from the same genetic screen (Hu et al., 2006) . These phenotypes have been confirmed with a second eak-3 allele (data not shown) and are consistent with the hypothesis that EAK-3 functions in parallel to AKT-1. eak-3 mutants did not enhance the dauer arrest phenotype of eak-4(mg348), sdf-9(ut187) (Fig. 1A) , or eak-6 (mg329) (Fig. S1A ), suggesting that EAK-3 functions in the same pathway or complex as EAK-4, SDF-9, and EAK-6 (Hu et al., 2006) .
eak-3 mutants interact genetically with the DAF-2/InsR pathway
Genetic analysis suggests that EAK-3 functions in the DAF-2/InsR pathway. The 25°C dauer arrest phenotype of eak-3;akt-1 double mutants was suppressed by a null mutation in daf-16/FoxO (Fig. 1B) . daf-16/FoxO mutations specifically suppress phenotypes caused by DAF-2/InsR pathway mutations (Gottlieb and Ruvkun, 1994; Vowels and Thomas, 1992) . daf-16/FoxO mutation also suppressed the 27°C dauer arrest phenotype of eak-3 single mutants (Fig. 1C) . Furthermore, daf-18/PTEN loss-of-function and akt-1 gain-of-function mutations, which also suppress the dauer arrest phenotype of insulin-like pathway mutations (Gil et al., 1999; Gottlieb and Ruvkun, 1994; Ogg and Ruvkun, 1998; Paradis and Ruvkun, 1998; Vowels and Thomas, 1992) , suppressed eak-3 (mg344) dauer arrest at 27°C (Fig. 1D ). Mutations in daf-3/ SMAD (Patterson et al., 1997) , which specifically suppress the dauer arrest phenotype of daf-7/TGFβ pathway mutants (Gottlieb and Ruvkun, 1994; Thomas et al., 1993; Vowels and Thomas, 1992) , and osm-5/Tg737 (Haycraft et al., 2001) , which specifically suppress the dauer arrest phenotype of daf-11/GC mutants (Vowels and Thomas, 1992) , did not suppress dauer arrest in eak-3;akt-1 double mutants (Fig. 1B) , suggesting that EAK-3 does not impinge upon those pathways. Consistent with the placement of eak-3 in the DAF-2/InsR pathway, eak-3(mg344) enhances the weak dauer arrest phenotype of age-1/PI3K and pdk-1 partial loss-of-function mutants (Fig. S1B ). eak-3(mg344) also enhanced dauer arrest of daf-2 (e1370) at 15°C (Fig. S1C ). eak-3(mg344) did not enhance the dauer arrest phenotype of an akt-2 null mutant ( Fig. S1B) , suggesting that EAK-3 may function in the same pathway as AKT-2.
eak-3 mutants interact genetically with the DAF-9/CYP27A1 hormonal pathway Since DAF-9/CYP27A1 overexpression suppresses dauer arrest in sdf-9 mutants (Ohkura et al., 2003) and EAK-3 and SDF-9 may function in the same pathway (Fig. 1A) , we determined whether eak-3 interacts genetically with components of the DAF-9/CYP27A1 hormonal pathway. We were not able to assess the effect of eak-3 mutation in a daf-9 null background, as daf-9 null mutants undergo nonconditional dauer arrest (Gerisch et al., 2001; Jia et al., 2002) . eak-3 (mg344) did enhance dauer arrest of the partial loss-of-function allele daf-9(k182), which has a weak dauer arrest phenotype at 25°C ( Fig. 2A) (Gerisch et al., 2001) . As is the case for all dauer-constitutive mutants, a daf-12 null mutation fully suppressed dauer arrest in eak-3;akt-1 and eak-3(mg344) mutants (Figs. 2B and C). daf-36/Rieske mutants exhibit weak dauer arrest at 25°C (Figs. 2D and E) (Rottiers et al., 2006) , and ncr-1 and ncr-2 single mutants do not arrest as dauers at 25°C (Fig. S1D) (Li et al., 2004) . eak-3(mg344) enhanced the dauer arrest phenotype of a daf-36/Rieske null allele, although not to the extent that it enhanced akt-1(mg306) dauer arrest (Fig. 2D) . eak-3(mg344) also enhanced the dauer arrest phenotype of a ncr-1 null allele but did not enhance the dauer arrest phenotype of a ncr-2 null allele (Fig. S1D) . These results suggest that eak-3 may act in parallel to ncr-1 and daf-36/Rieske to inhibit dauer arrest.
The ability of eak-3(mg344) to enhance dauer arrest phenotypes of both akt-1 and daf-36/Rieske mutants suggests that AKT-1 and DAF-36/Rieske could conceivably act in the same pathway. To test this possibility, we determined whether inactivation of akt-1 by RNAi would enhance the dauer arrest phenotype of a daf-36/Rieske loss-of-function mutant (the proximity of akt-1 and daf-36/Rieske genes in the C. elegans genome prevented the construction of a daf-36 akt-1 double mutant). akt-1 RNAi enhanced dauer arrest in both eak-3 and daf-36/Rieske mutants to a comparable extent (Fig. 2E ). Since this daf-36/Rieske allele is a null allele (Rottiers et al., 2006) , AKT-1, EAK-3, and DAF-36/Rieske likely act in parallel pathways.
eak-3 regulation of lifespan DAF-2/InsR and DAF-9/CYP27A1 pathways regulate organismal lifespan (Broue et al., 2007; Finch and Ruvkun, 2001; Gerisch et al., 2001 Gerisch et al., , 2007 Jia et al., 2002; Kenyon, 2005; Rottiers et al., 2006) . Since eak-3 interacts genetically with both DAF-2/InsR and DAF-9/CYP27A1 pathways, we assayed eak-3 mutants for lifespan phenotypes. In contrast to daf-2(e1370), which exhibits approximately 2-fold lifespan extension compared to wild-type animals, neither eak-3 (mg344) nor eak-3;akt-1 double mutants lived longer than wild-type animals (Figs. 3A and C, Table 1 ). As previously reported (Hu et al., 2006) , akt-1(mg306) animals lived slightly longer than wild-type animals, and other eak single mutant and eak;akt-1 double mutants had lifespans comparable to eak-3 single and eak-3;akt-1 double mutant animals (Table 1) . Although mutation of eak genes did not significantly affect Table S1 .
lifespan in wild-type backgrounds, eak-3;akt-1 animals had slightly shorter lifespans than akt-1(mg306) single mutants ( Fig. 3A and Table 1 ), as did other eak;akt-1 double mutants (Table 1) .
To further investigate the role of eak-3 in lifespan regulation, we determined the effect of eak-3 mutation on lifespan in daf-2/ InsR and daf-16/FoxO mutant backgrounds. At 20°C, eak-3 daf-2 double mutants exhibited extended longevity compared to daf-2 single mutants (Fig. 3B) . This is consistent with the enhancement of daf-2(e1370) dauer arrest by eak-3 mutation (Fig. S1C) . eak-3 mutation did not affect the lifespan of daf-16/ FoxO mutants (Fig. 3C) , suggesting that the lifespan extending effects of eak-3 mutation in a daf-2(e1370) background ( Table S1 .
Cloning of eak-3
We used single nucleotide polymorphism mapping (Wicks et al., 2001 ) to localize eak-3 to a ∼ 210-kb genomic interval on the left arm of chromosome III. Rescue assays with pools of overlapping ∼ 10-12 kb PCR products (Winston et al., 2002) that spanned the eak-3 interval indicated that eak-3 likely corresponds to the open reading frame Y92C3A.3. Sequencing of predicted exons and splice junctions of Y92C3A.3 in three eak-3 alleles identified distinct point mutations in each allele (Fig. S2) . The Y92C3A.3 open reading frame lies within a large intron of cdh-12, a cadherin gene that lies on the opposite genomic strand. A genomic PCR fragment corresponding to this intron and containing the predicted Y92C3A.3 promoter, open reading frame, and 3′ untranslated region rescued the eak-3 mutant phenotype in 1 of 4 transgenic lines (data not shown).
The eak-3 promoter drives transcription specifically in the XXX cells
To determine where eak-3 is expressed in intact animals, we generated transgenic animals harboring a construct consisting of the predicted eak-3 promoter fused to GFP (eak-3p∷GFP). These animals exhibited specific GFP expression in two cells in the head, the position and morphology of which suggested that they were the XXX cells (Fig. 4A) . Colocalization of GFP and RFP in animals coexpressing eak-3p∷GFP and sdf-9p∷RFP, which marks the cytoplasm of the XXX cells (Hu et al., 2006; Ohkura et al., 2003) , confirmed that the eak-3 promoter is specifically active in the XXX cells (Fig. 4A ).
An EAK-3∷GFP fusion protein localizes to the plasma membrane of the XXX cells
We isolated eak-3 cDNAs from total C. elegans RNA and confirmed the predicted cDNA structure (WormBase; www. wormbase.org; Fig. S2 ). EAK-3 has no statistically significant amino acid similarity to known proteins. Strikingly, 4 of the first 5 predicted amino-terminal amino acid residues are identical to EAK-4 (Hu et al., 2006) , including a glycine residue at position 2 that is invariant in N-myristoylated proteins (Maurer-Stroh et al., 2002) . However, the sixth amino acid residue, which is conserved in most N-myristoylated proteins (Maurer-Stroh et al., 2002) , is not conserved in EAK-3.
We generated transgenic animals harboring a C-terminal EAK-3∷GFP translational fusion construct to determine the subcellular localization of EAK-3∷GFP. EAK-3∷GFP localized to the plasma membrane of the XXX cells. This localization was confirmed by visualization of animals coexpressing EAK-3∷GFP and sdf-9p∷RFP (Fig. 4B) .
To examine the role of the N-myristoylation motif in EAK-3∷GFP plasma membrane localization, we tested the effect of mutagenizing the glycine at residue 2 that is absolutely required for N-myristoylation on the subcellular localization of EAK-3∷GFP. We generated transgenic animals expressing wild-type EAK-3∷GFP and mutant EAK-3∷GFP with glycine at residue 2 mutated to alanine (G2A). Whereas wild-type EAK-3∷GFP localizes to the plasma membrane, the G2A mutation abrogates membrane association and results in relocalization to the cytoplasm (Figs. 4B and C) . Thus, the glycine that is absolutely required for N-myristoylation is also required for EAK-3∷GFP plasma membrane association. Five of six amino acids immediately following the putative N-myristoylation motif in EAK-3 are either lysine or arginine (residues 6-11; Fig. S2 ) and may contribute to the membrane localization of EAK-3.
EAK proteins do not regulate DAF-16∷GFP subcellular localization
Insulin-like signaling pathways inhibit FoxO transcription factors via a conserved mechanism of Akt-mediated phosphorylation and subsequent cytoplasmic sequestration (Barthel et al., 2005; Henderson and Johnson, 2001; Lee et al., 2001; Lin et al., 2001; Vogt et al., 2005) . The suppression of eak-3 mutant phenotypes by daf-16/FoxO mutation suggests that in wild-type animals, EAK-3 also inhibits DAF-16/FoxO function. To deter- Combined results from two independent experiments are shown. Lifespans from one of these experiments have been reported previously (Hu et al., 2006) . Abbreviations: SD, standard deviation.
mine whether EAK-3 regulates DAF-16/FoxO nuclear translocation, we examined the subcellular localization of a DAF-16∷GFP translational fusion (Henderson and Johnson, 2001 ) in wild-type, akt-1(mg306), and eak-3(mg344) mutant animals. In wild-type animals, DAF-16∷GFP is predominantly cytoplasmic (Fig. 5A) , consistent with the presence of intact DAF-2/InsR signaling. Mutation of akt-1 results in nuclear translocation of DAF-16∷GFP, consistent with previous results (Hertweck et al., 2004) . In contrast, eak-3 mutation has no effect on DAF-16∷GFP subcellular localization, indicating that EAK-3 does not regulate the subcellular distribution of DAF-16/FoxO.
Since sdf-9 and eak-6 likely function in the same pathway as eak-3 (Figs. 1A and S1A) , we also assayed DAF-16∷GFP subcellular localization in sdf-9 and eak-6 mutant backgrounds. As expected, neither sdf-9 nor eak-6 mutation affected DAF-16∷GFP subcellular localization (Fig. S3A) .
EAK proteins regulate DAF-16/FoxO target gene expression in an akt-1 mutant background
In C. elegans, nuclear translocation of DAF-16/FoxO is not sufficient for full DAF-16/FoxO activation (Berdichevsky et al., 2006; Hertweck et al., 2004; Lin et al., 2001) , indicating that nuclear DAF-16/FoxO activity may be regulated independently of Akt. We tested the ability of EAK-3 to regulate the activity of nuclear DAF-16/FoxO by constructing wild-type and mutant animals harboring a sod-3p∷GFP reporter construct (Libina et al., 2003) . DAF-16/FoxO directly activates transcription of sod-3 , and the sod-3p∷GFP reporter serves as a readout for DAF-16/FoxO activity (Libina et al., 2003) . Wildtype animals exhibited baseline expression of sod-3p∷GFP in the head and the tail without significant GFP expression in the intestine or body wall muscle (Fig. 5B) . eak-3 mutation did not affect sod-3p∷GFP expression significantly in a wild-type background. Since DAF-16/FoxO remains in the cytoplasm in eak-3 mutants (Fig. 5A) , this result demonstrates that in the absence of nuclear DAF-16/FoxO, EAK-3 does not regulate sod-3p∷GFP transcription. akt-1 mutation increased sod3p∷GFP transcription above baseline in the body wall muscle. However, intestinal sod-3p∷GFP expression remained comparable to that seen in wild-type animals. This indicates that in body wall muscle, AKT-1 may be the primary regulator of DAF-16/FoxO-mediated activation of the sod-3 promoter. Interestingly, in the eak-3;akt-1 double mutant background, sod-3p∷GFP expression was induced in both body wall muscle and intestine, and intestinal GFP expression was substantially greater in eak-3;akt-1 double mutants compared to akt-1 single mutants (Fig. 5B ). This indicates that in akt-1 mutant animals, EAK-3 inhibits sod-3 transcription, perhaps in a tissue-specific manner. Since the eak-3 promoter drives expression specifically in the XXX cells (Fig. 4) , EAK-3 functions nonautonomously to inhibit nuclear DAF-16/FoxO activity in the intestine. We observed similar sod-3p∷GFP expression patterns in sdf-9, eak-6, akt-1 sdf-9, and eak-6;akt-1 mutants, consistent with SDF-9, EAK-6, and EAK-3 functioning in the same pathway or complex in the XXX cells (Fig. S3B) .
We confirmed these results by examining the effects of eak-3, eak-4, sdf-9, and eak-6 mutations on the expression of endogenous sod-3. We isolated total RNA from wild-type and Fig. 5 . Effects of eak-3 mutation on DAF-16/FoxO subcellular localization and activity in vivo. (A) Wild-type and mutant animals (late L1 to early L2 larvae) harboring a DAF-16∷GFP translational fusion were assayed for DAF-16∷GFP subcellular localization. (B) Wild-type and mutant animals (late L1 to early L2 larvae) harboring a sod-3p∷GFP promoter fusion were assayed for GFP expression. Identical exposure times were used to photograph all animals harboring a specific GFP reporter. Representative images are shown.
mutant animals and performed quantitative real-time reverse transcription PCR using gene-specific primers for sod-3. Whereas relative endogenous sod-3 mRNA levels were modestly increased in eak and akt-1 single mutants compared to wild-type animals, they were dramatically elevated in all eak; akt-1 double mutant animals compared to single mutants (Fig. 6A) . These results indicate that EAK proteins function in parallel to AKT-1 to inhibit DAF-16/FoxO activity on endogenous promoters.
In light of the observation that dauer arrest in eak-3;akt-1 double mutants requires both daf-16/FoxO (Fig. 1) and daf-12 (Fig. 2) , we measured endogenous sod-3 mRNA expression in eak-3;akt-1 double mutants after reduction of daf-16/FoxO or daf-12 activity by RNAi. RNAi of either daf-16/FoxO or daf-12 reduced endogenous sod-3 expression approximately seven-fold (Fig. 6B) , indicating that in eak-3;akt-1 double mutants, DAF-12 is also required for the expression of certain DAF-16/FoxO targets. daf-9 RNAi had no effect on sod-3 expression levels.
Since DAF-36/Rieske may function in parallel to both EAK-3 (Fig. 2D ) and AKT-1 (Fig. 2E) to inhibit dauer arrest, we measured endogenous sod-3 mRNA levels in eak-3;daf-36 double mutants and in daf-36 single mutants after inactivating akt-1 by RNAi. sod-3 mRNA levels were significantly increased in eak-3;daf-36 double mutants compared to eak-3 and daf-36 single mutants (Fig. 6A) . akt-1 RNAi dramatically increased sod-3 mRNA levels in both eak-3 and daf-36 mutants (Fig. 6C ). Taken together with the synthetic dauer-constitutive phenotype of eak-3;daf-36 double mutants at 25°C (Fig. 2D ) and the enhancement of dauer arrest in daf-36/Rieske mutants by akt-1 RNAi (Fig. 2E) , this result suggests that DAF-36 and EAK-3 act in parallel to AKT-1 and to each other to inhibit sod-3 expression.
Discussion
EAK-3 may function in an endocrine pathway
The endocrine nature of EAK-3 function is supported by the observation that eak-3 mutation enhances a systemic phenotype, namely dauer arrest (Figs. 1 and 2 ), in spite of the fact that the eak-3 promoter is only active in the XXX cells (Fig. 4) . Furthermore, eak-3 mutation enhances DAF-16/FoxO target gene expression nonautonomously (Fig. 5) . These results are consistent with at least two models of EAK-3 function. EAK-3 could inhibit the activity of a hormone secreted by the XXX cells that activates nuclear DAF-16/FoxO. However, the fact that laser ablation of the XXX cells results in a dauer-constitutive phenotype suppressed by loss of daf-16/FoxO activity in the rest of the animal (Ohkura et al., 2003) rather than a dauer-defective phenotype suggests that the XXX cells normally inhibit DAF-16/FoxO. This leads us to favor an alternative model whereby EAK-3 promotes the activity of a hormone secreted from the XXX cells that inhibits nuclear DAF-16/FoxO activity (Fig. 7) .
One plausible model of nonautonomous DAF-16/FoxO regulation by EAK-3 invokes the secretion of insulin-like peptide hormones that activate DAF-2/InsR on the surface of target cells. If EAK-3 inhibits DAF-16/FoxO by promoting the activity of a DAF-2/InsR agonist ligand, then eak-3 loss-offunction should phenocopy daf-2 loss-of-function. However, in contrast to the extended lifespan exhibited by sixteen independent daf-2 loss-of-function alleles (Gems et al., 1998) , eak-3 loss-of-function mutants have normal lifespans (Fig. 3 and Table 1 ). Furthermore, whereas daf-2 loss-of-function promotes DAF-16∷GFP nuclear localization (Henderson and Johnson, 2001; Lee et al., 2001; Lin et al., 2001) , eak-3 loss-offunction mutation has no effect on DAF-16∷GFP subcellular distribution (Fig. 5A ). These observations suggest that EAK-3 does not regulate the synthesis or secretion of DAF-2/InsR ligands.
Genetic interactions of eak-3 with the DAF-9/CYP27A1 hormonal pathway (Figs. 2 and S1D) suggest that EAK-3 may regulate the synthesis and/or secretion of a steroid hormone. Similar interactions have been described for sdf-9, a gene that is also specifically expressed in the XXX cells (Hu et al., 2006; Ohkura et al., 2003) and that also emerged from our genetic screen (Hu et al., 2006) . Intriguingly, daf-9/CYP27A1 is expressed in the XXX cells (Ohkura et al., 2003) as well as in other tissues (Gerisch et al., 2001; Jia et al., 2002) . Overexpression of daf-9/CYP27A1 can rescue the sdf-9 mutant phenotype (Ohkura et al., 2003) , suggesting that DAF-9/ CYP27A1 functions either parallel to or downstream of SDF-9. The lack of phenotypic enhancement in an eak-3;sdf-9 double mutant (Fig. 1A) and the colocalization of EAK-3 and SDF-9 in the XXX cells (Fig. 4) suggest that DAF-9/CYP27A1 may also function parallel to or downstream of EAK-3. These results would be consistent with EAK-3 and SDF-9 functioning in the XXX cells to promote the DAF-9/CYP27A1-dependent synthesis of a steroid hormone that inhibits DAF-16/FoxO activity in target tissues. In this scenario, DAF-9/CYP27A1 expressed in the XXX cells would be predicted to have a function upstream of DAF-16/FoxO. The observation that daf-16/FoxO mutations do not suppress the dauer arrest phenotype of daf-9/CYP27A1 mutants (Gerisch et al., 2001; Jia et al., 2002) suggests that DAF-9/CYP27A1 also functions in parallel to or downstream of DAF-16/FoxO in other tissues.
eak-3 and sdf-9 mutations enhance dauer arrest in ncr-1 mutants but do not influence dauer arrest in ncr-2 mutants (Fig.  S1D) (Ohkura et al., 2003) . The observation that the ncr-2 promoter is only active in the XXX cells during early larval stages (Li et al., 2004) suggests that eak-3 and sdf-9 mutations may fail to enhance dauer arrest in ncr-2 mutants by virtue of EAK-3 and SDF-9 acting in the same pathway as NCR-2 in the XXX cells. Alternatively, this may be a consequence of the stronger phenotype of ncr-1 mutants compared to ncr-2 mutants (Li et al., 2004) . It is not known whether the difference in ncr-1 and ncr-2 mutant phenotypes is a consequence of the distinct expression patterns of ncr-1 and ncr-2 or of intrinsic differences in the function of NCR-1 and NCR-2 proteins.
EAK-3 decouples DAF-16/FoxO regulation of dauer arrest and lifespan
The physiological consequences of DAF-16/FoxO activation are determined at least in part by where in the animal and when during its life history DAF-2/InsR signaling is inhibited. For example, DAF-16/FoxO activity in neurons has disproportionate effects on dauer arrest compared to lifespan, whereas intestinal DAF-16/FoxO activity affects lifespan more prominently than dauer arrest (Libina et al., 2003) . Also, transient activation of DAF-16/FoxO during early larval development promotes dauer arrest without impacting organismal lifespan, whereas DAF-16/FoxO activation during early adulthood promotes extended longevity (Dillin et al., 2002) . Although some proteins have been implicated in the regulation of lifespan- specific DAF-16/FoxO functions (Berman and Kenyon, 2006; Wolff et al., 2006) , to our knowledge, EAK-3 is the first protein described that primarily regulates DAF-16/FoxO dauer-inducing activity. The ability of eak-3 mutation to extend the lifespan of daf-2(e1370) mutants at 20°C (Fig. 3B) is consistent with its enhancement of dauer arrest in daf-2(e1370) mutants at low temperatures (Fig. S1C) and suggests that EAK-3 can regulate lifespan in certain contexts.
The mechanisms underlying EAK-3 decoupling of the dauer arrest and lifespan regulatory functions of DAF-16/FoxO remain obscure. The eak-3 promoter is active from late embryogenesis through young adulthood (data not shown), suggesting that eak-3 expression is not limited to the developmental stages during which the dauer arrest decision is made. Furthermore, although intestinal DAF-16/FoxO activity correlates with lifespan extension (Libina et al., 2003) , eak-3;akt-1 mutants also exhibit increased intestinal DAF-16/FoxO activity during late larval stages (data not shown) but do not have extended longevity (Fig.  3A and Table 1 ). This suggests that activation of intestinal DAF-16/FoxO per se is not sufficient to extend organismal lifespan.
EAK-3 regulates DAF-16/FoxO activity
Since daf-16/FoxO loss-of-function fully suppresses eak-3 dauer arrest phenotypes (Fig. 1) , DAF-16/FoxO is a major genetic target of EAK-3. This is consistent with the observation that loss-of-function mutations in daf-18/PTEN and gain-offunction mutations in akt-1 also suppress eak-3 mutant phenotypes (Fig. 1D) . The design of the genetic screen from which eak-3 was isolated (Hu et al., 2006) , and the regulatory effects of EAK-3 on DAF-16/FoxO activity (Figs. 5B and 6) suggest that EAK-3 functions in parallel to AKT-1 to inhibit DAF-16/ FoxO activity.
In contrast to its interactions with akt-1 mutants, eak-3 mutation did not enhance dauer arrest in an akt-2 mutant background (Fig. S1B ). This could be secondary to the weaker phenotypic effects of akt-2 loss-of-function compared to akt-1 loss-of-function (Hertweck et al., 2004; Paradis and Ruvkun, 1998; Quevedo et al., 2007) . Alternatively, EAK-3 may inhibit DAF-16/FoxO by activating AKT-2. This would not be inconsistent with the lack of effect of eak-3 mutation on DAF-16∷GFP subcellular distribution (Fig. 5A) , as AKT-2 does not strongly influence DAF-16∷GFP localization (Hertweck et al., 2004) . Reporters driven by akt-1 and akt-2 promoters are both widely expressed (Paradis and Ruvkun, 1998) , suggesting that differences in spatial expression patterns do not account for the differential phenotypic effects of eak-3 mutation in akt-1 and akt-2 mutant backgrounds.
Mechanisms of DAF-16/FoxO regulation
Most proteins known to regulate DAF-16/FoxO do so by controlling its subcellular distribution. For example, the kinases JNK-1 (Oh et al., 2005) and CST-1 (Lehtinen et al., 2006) and the intestinal protein KRI-1 (Berman and Kenyon, 2006) promote DAF-16/FoxO nuclear translocation. Conversely, AKT-1 (Hertweck et al., 2004) and the 14-3-3 proteins PAR-5 (Berdichevsky et al., 2006) and FTT-2 (Berdichevsky et al., 2006; Li et al., 2007) promote the cytoplasmic sequestration of DAF-16/FoxO. Intriguingly, although FTT-2 inhibits DAF-16/ FoxO nuclear localization, it appears to be required for SIR-2.1-dependent activation of nuclear DAF-16/FoxO (Berdichevsky et al., 2006; Wang et al., 2006) .
Two proteins, SMK-1 (Wolff et al., 2006) and SIR-2.1 (Berdichevsky et al., 2006) , have been shown to potentiate DAF-16/FoxO activity without affecting DAF-16/FoxO subcellular localization; interestingly, both regulate DAF-16/FoxOdependent lifespan extension without strongly impacting DAF-16/FoxO-mediated dauer arrest (Tissenbaum and Guarente, 2001; Wolff et al., 2006) . It is conceivable that EAK-3 prevents dauer arrest by inhibiting molecules that function analogously to SMK-1 and SIR-2.1 in dauer regulation.
DAF-12 may regulate a subset of DAF-16/FoxO target genes
We have shown that DAF-12 is required for maximal endogenous sod-3 expression in eak-3;akt-1 double mutants (Fig. 6B) . DAF-12 is also required for full expression of intestinal sod-3∷GFP in eak-3;akt-1 double mutants (data not shown). To our knowledge, this is the first demonstration that DAF-12 is required for the expression of a specific DAF-16/ FoxO target gene. The requirement of DAF-12 for the dauer arrest and sod-3 expression phenotypes of eak-3 mutants (Figs. 2 and 6B) raises the possibility that EAK-3 may regulate DAF-16/FoxO target gene expression indirectly via DAF-12. For example, nuclear DAF-16/FoxO and unliganded DAF-12 could act in parallel to activate intestinal sod-3 expression by converging on the sod-3 promoter. sod-3 expression would be inhibited by activation of either AKT-1 (resulting in DAF-16/ FoxO phosphorylation and cytoplasmic sequestration) or EAK-3 (resulting in dafachronic acid synthesis and binding to DAF-12). daf-12 RNAi had no effect on DAF-16∷GFP nuclear localization in wild-type, akt-1 mutant, or eak-3 mutant animals, and daf-9 RNAi did not affect DAF-16∷GFP localization in wild-type or akt-1 mutants and resulted in DAF-16∷GFP nuclear localization in less than 10% of eak-3 mutants (data not shown), suggesting that the major regulatory effect of the hormonal pathway on DAF-16/FoxO target gene expression does not occur via changes in DAF-16/FoxO subcellular distribution.
This model also accommodates the observation that DAF-36/Rieske may act in parallel to both AKT-1 and EAK-3 (Figs. 2D, 2E , 6A, and 6C), as DAF-36/Rieske is thought to participate in the biosynthesis of dafachronic acids (Rottiers et al., 2006) . Although both EAK-3 and DAF-36/Rieske may act in dafachronic acid biosynthetic pathways, they may function in parallel by virtue of their expression in distinct cells; expression of daf-36 in the XXX cells has not been observed (Rottiers et al., 2006) .
A model for EAK-3 function
Based on our data as well as previously published work, we propose a model for EAK-3 function (Fig. 7) . In the XXX cells, EAK-3 acts together with other EAK proteins (Hu et al., 2006) to promote the synthesis and/or secretion of a hormone that regulates the expression of DAF-16/FoxO target genes nonautonomously. XXX-specific expression of akt-1 rescues the dauer arrest phenotype of an eak-4;akt-1 double mutant (Hu et al., 2006) , suggesting that AKT-1 functions in the XXX cells to prevent dauer arrest. AKT-1 may target a protein distinct from DAF-16/FoxO in the XXX cells, since the major isoform of DAF-16/FoxO that regulates dauer arrest is not expressed at detectable levels in the XXX cells (Hu et al., 2006) . In the XXX cells, EAK-3, other EAK proteins, and AKT-1 may regulate one or more proteins involved in hormone synthesis and/or secretion, such as DAF-9/ CYP27A1 or other undiscovered proteins (indicated by the orange shape).
In target cells, AKT-1 functions to promote DAF-16/FoxO cytoplasmic sequestration, and the steroid hormone (or hormones) produced in the XXX cells acts in parallel to AKT-1 to inhibit the transcription of DAF-16/FoxO target genes, possibly via DAF-12. In wild-type animals, DAF-16/FoxO is sequestered in the cytoplasm, and DAF-12 is bound to steroid hormone ligands (Fig. 7A ). When akt-1 is mutated, DAF-16/ FoxO translocates to the nucleus; however, certain DAF-16/ FoxO target genes such as sod-3 are not fully induced in the presence of liganded DAF-12. In eak-3;akt-1 double mutants, nuclear DAF-16/FoxO and unliganded DAF-12 cooperate to promote dauer arrest by regulating the expression of a subset of DAF-16/FoxO target genes (Fig. 7B) . This model does not exclude the possibility that EAK-3 may also inhibit the expression of DAF-16/FoxO target genes through DAF-12-independent mechanisms.
It is noteworthy that the genetic screen that yielded eak-3 also identified three other genes that remain to be characterized. These genes could encode components of the hormone biosynthetic or regulatory machinery in the XXX cells as well as mediators of hormonal effects in target tissues. Their molecular identities and functions will illuminate the EAK-3 endocrine pathway and may also shed light on how FoxO transcription factors are regulated in mammals.
